Literature DB >> 23445298

Prolactin in obese children: a bridge between inflammation and metabolic-endocrine dysfunction.

Valeria Chirico1, Salvatore Cannavò, Antonio Lacquaniti, Vincenzo Salpietro, Mattia Mandolfino, Petronilla Daniela Romeo, Oana Cotta, Caterina Munafò, Grazia Giorgianni, Carmelo Salpietro, Teresa Arrigo.   

Abstract

OBJECTIVE: Adipocytes, regulated by insulin, represent the major peripheral source of prolactin (PRL), which play a pivotal role in energy balance, acting on adipogenesis and lipolysis. The aim of this study was to investigate whether PRL was associated with obesity-related inflammatory status and metabolic parameters. The diagnostic and prognostic role of PRL for metabolic syndrome (MS) was assessed. The effects of short-term lifestyle therapy on PRL levels were evaluated.
SUBJECTS: Prolactin was assessed in 94 obese patients and compared with 40 healthy children (HS).Patients were followed up for 1 year. Receiver operating characteristics (ROC) analysis was employed to find the best cut-off values capable of identifying MS in obese children for PRL, IL-6 and TNF-α. Kaplan-Meier curves were also generated. Adjusted risk estimates for MS were calculated using Cox proportional hazard regression analysis. An obesity intervention programme was administered for 12 months.
RESULTS: Prolactin levels were lower in obese patients than controls (P < 0·0001). PRL was found to be inversely correlated with BMI, IL-6 and HOMA-IR, whereas a direct correlation was found with HDL values. At ROC analysis, PRL showed higher sensitivity and specificity than IL-6 and TNF-α in identifying MS in obese children. Cox proportional hazard regression analysis showed that PRL predicted MS independently of other potential confounders. The lifestyle intervention improved PRL and metabolic parameters.
CONCLUSIONS: Prolactin represents a prognostic marker for obese children and a predictive factor for progression to MS. PRL measurement may be useful as part of the endocrine work-up of obese children.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23445298     DOI: 10.1111/cen.12183

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  18 in total

1.  Is prolactin the missing link in adipose tissue dysfunction of polycystic ovary syndrome patients?

Authors:  Alice Albu; Suzana Florea; Simona Fica
Journal:  Endocrine       Date:  2015-06-12       Impact factor: 3.633

2.  Neuroadaptations in the striatal proteome of the rat following prolonged excessive sucrose intake.

Authors:  Selina Ahmed; Mohammed Abul Kashem; Ranjana Sarker; Eakhlas U Ahmed; Garth A Hargreaves; Iain S McGregor
Journal:  Neurochem Res       Date:  2014-03-15       Impact factor: 3.996

3.  Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans.

Authors:  Antonio J Ponce; Tomás Galván-Salas; Ricardo M Lerma-Alvarado; Xarubet Ruiz-Herrera; Tomás Hernández-Cortés; Rodrigo Valencia-Jiménez; Laura E Cárdenas-Rodríguez; Gonzalo Martínez de la Escalera; Carmen Clapp; Yazmín Macotela
Journal:  Endocrine       Date:  2020-01-09       Impact factor: 3.633

4.  Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.

Authors:  Rita Indirli; Emanuele Ferrante; Elisa Sala; Claudia Giavoli; Giovanna Mantovani; Maura Arosio
Journal:  Horm Cancer       Date:  2019-04-18       Impact factor: 3.869

Review 5.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

6.  Circulating prolactin level is increased in metabolically healthy obesity.

Authors:  Jia Liu; Lin Zhang; Jing Fu; Qiu Wang; Guang Wang
Journal:  Endocr Connect       Date:  2021-04-29       Impact factor: 3.335

Review 7.  Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".

Authors:  Sara Manti; Claudio Romano; Valeria Chirico; Martina Filippelli; Caterina Cuppari; Italia Loddo; Carmelo Salpietro; Teresa Arrigo
Journal:  Hepat Mon       Date:  2014-05-01       Impact factor: 0.660

Review 8.  Adrenal disorders and the paediatric brain: pathophysiological considerations and clinical implications.

Authors:  Vincenzo Salpietro; Agata Polizzi; Gabriella Di Rosa; Anna Claudia Romeo; Valeria Dipasquale; Paolo Morabito; Valeria Chirico; Teresa Arrigo; Martino Ruggieri
Journal:  Int J Endocrinol       Date:  2014-09-03       Impact factor: 3.257

9.  Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients.

Authors:  Rui Wang; Christopher A Ross; Huan Cai; Wei-Na Cong; Caitlin M Daimon; Olga D Carlson; Josephine M Egan; Sana Siddiqui; Stuart Maudsley; Bronwen Martin
Journal:  Front Physiol       Date:  2014-06-23       Impact factor: 4.566

Review 10.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.